Michel Petignat

Swiss Rockets Signs Strategic Exclusive Licensing Agreement with MGI and Complete Genomics, Subject to MGI Shareholder Approval

Bimiralisib, Topical PI3K/mTOR Inhibitor Shows Up To 92% Clearance Rate And Superior Tolerability In Proof-Of-Concept Actinic Keratosis Study

Swiss Rockets Welcomes Former Genentech Business Development Executive Thomas Zioncheck as Chief Strategy Officer